Seelos Therapeutics Inc (SEELQ)

[eicoman]

correction , 2 PH2 studies were done, the first on on mild to moderate patients the second on severe ED patients, and note:

"relative to many recently reported investigations of ED therapy 13,15,17 both studies contained greater percentages of patients with cardiovascular disease and diabetes."

http://www.nature.com/ijir/journal/v15/n1/full/3900940a.html

the point I'm trying to make is it's important to look at the type of patients and how Vitaros works for different types of patients.